Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784499 | 0.91 | NPC1 (0.59) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3781356 | 0.88 | NPC1 (0.56) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3792027 | 0.86 | CHRM3 (0.58) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3790375 | 0.85 | HDAC1 (0.67) | MGLLNPC1RAB9AHDAC1HDAC2 | |
| SCHEMBL3785606 | 0.85 | MGLL (0.57) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3781969 | 0.84 | PTPN1 (0.55) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3790186 | 0.83 | MGLL (0.54) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3799839 | 0.83 | MGLL (0.54) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3789479 | 0.82 | CASP3 (0.60) | MGLLNPC1RAB9APTPN1HDAC1 | |
| SCHEMBL3787235 | 0.82 | MGLL (0.53) | MGLLNPC1RAB9APTPN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MGLL 1314/4885NPC1 724/4885RAB9A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.